Biosimilar and Generic Semaglutide: What's Actually in Development
Semaglutide's patent position varies by country, and that's driving very different generic and biosimilar timelines around the world.
By the GLP Semaglutide editorial team · Last updated January 15, 2026
Semaglutide is a peptide drug, which means a true 'generic' version would technically be regulated as a biosimilar in most jurisdictions rather than a small-molecule generic, with its own separate approval pathway and comparability requirements.
Patent status varies by market
Novo Nordisk's semaglutide patent protection differs by country, which is part of why some markets (including India, where compulsory licensing and patent rules differ from the U.S.) have seen earlier movement toward lower-cost versions than others.
What to watch
Biosimilar approval requires demonstrating no clinically meaningful difference from the reference product, a process that takes years even after patent barriers clear. Company pipeline disclosures and national patent office filings are the most reliable primary sources for tracking specific timelines.
Primary sources